





## Supplementary figure S1.

**Supplementary figure S1.** Experimental timeline. Rats were administered an injection with Sugen 5416 (SU; 20 mg/kg s.c.) and housed under hypoxic condition (9% O<sub>2</sub>) for 3 weeks followed by 3 days under normoxic condition (21% O<sub>2</sub>). Treatment was administered with ACTZ (1.7 mg/ml) *ad libitum* in the drinking water from Day 7 to Day 24. Control rats were treated with ACTZ in normoxia for the same time period. † This represents the study endpoint when animals were killed.



## Supplementary figure S2.

**Supplementary figure S2.** Hemodynamic characteristics of experimental pulmonary hypertension. **(A)** Right Ventricular Systolic Pressure (RVSP), **(B)** Left Ventricular Systolic Pressure (LVSP), **(C)** Right ventricular hypertrophy assessed by Fulton's Index (ratio of right ventricular weight to left ventricular and septal weight) and **(D)** ratio of right ventricular weight to total body weight (RV/BW).  $n = 9 - 15$  animals per group. Statistical analysis by one-way ANOVA. Values are expressed as the mean  $\pm$  SEM (\*\* $p < 0.01$  and \*\*\*\* $p < 0.0001$ ).

<b>CONTROL</b>					
<b>TP Number</b>	<b>Age</b>	<b>Race</b>	<b>Sex</b>	<b>Procedure</b>	<b>Category</b>
12-09-P039e	56YR	White	Female	Surgery	Control - lung w/ M-L arteries
13-01-P049a	51YR	White	Male	Surgery	Control - lung w/ M-L arteries
<b>IPAH</b>					
11-06-P061d	56YR	White	Female	Transplant	IPAH - lung w/ M-L arteries
12-06-P009e	51YR	White	Male	Transplant	IPAH - lung w/ M-L arteries

## Supplementary Table S1.

**Supplementary Table S1.** Demographics and clinical information of human patients with IPAH and controls.